{"id":"https://openalex.org/W2590320103","doi":"https://doi.org/10.1182/blood.v114.22.3860.3860","title":"Bortezomib-Associated Peripheral Neuropathy: Relationship Between Clinical Neurophysiologic Evidence in Previously Untreated Multiple Myeloma Patients and Preclinical Characterization in a Mouse Model.","display_name":"Bortezomib-Associated Peripheral Neuropathy: Relationship Between Clinical Neurophysiologic Evidence in Previously Untreated Multiple Myeloma Patients and Preclinical Characterization in a Mouse Model.","publication_year":2009,"publication_date":"2009-11-20","ids":{"openalex":"https://openalex.org/W2590320103","doi":"https://doi.org/10.1182/blood.v114.22.3860.3860","mag":"2590320103"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v114.22.3860.3860","doi":"https://doi.org/10.1182/blood.v114.22.3860.3860","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v114.22.3860.3860","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5043526996","display_name":"Paul Gerard Guy Richardson","orcid":"https://orcid.org/0000-0002-7426-8865","observed_orcids":["https://orcid.org/0000-0002-7426-8865"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Paul G. Richardson","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA, USA,","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071730688","display_name":"Jordi Bruna","orcid":"https://orcid.org/0000-0001-6895-5047","observed_orcids":["https://orcid.org/0000-0001-6895-5047"]},"institutions":[{"id":"https://openalex.org/I123044942","display_name":"Universitat Aut\u00f2noma de Barcelona","ror":"https://ror.org/052g8jq94","country_code":"ES","type":"education","lineage":["https://openalex.org/I123044942"]},{"id":"https://openalex.org/I4210086696","display_name":"Biomedical Research Networking Center on Neurodegenerative Diseases","ror":"https://ror.org/00zca7903","country_code":"ES","type":"facility","lineage":["https://openalex.org/I4210086696"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Jordi Bruna","raw_affiliation_strings":["Institute of Neurosciences and CIBERNED, Universitat Autonoma de Barcelona, Bellaterra, Spain,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Institute of Neurosciences and CIBERNED, Universitat Autonoma de Barcelona, Bellaterra, Spain,","institution_ids":["https://openalex.org/I123044942","https://openalex.org/I4210086696"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102975649","display_name":"Anthony A. Amato","orcid":"https://orcid.org/0009-0006-3884-6644","observed_orcids":["https://orcid.org/0009-0006-3884-6644"]},"institutions":[{"id":"https://openalex.org/I1283280774","display_name":"Brigham and Women's Hospital","ror":"https://ror.org/04b6nzv94","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I48633490"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I4210161994","display_name":"Dana-Farber Brigham Cancer Center","ror":"https://ror.org/05rgrbr06","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I4210117453","https://openalex.org/I4210161994","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anthony A. Amato","raw_affiliation_strings":["Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, MA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, MA, USA,","institution_ids":["https://openalex.org/I1283280774","https://openalex.org/I4210117453","https://openalex.org/I4210161994"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015194708","display_name":"Esther Udina","orcid":"https://orcid.org/0000-0003-1954-8562","observed_orcids":["https://orcid.org/0000-0003-1954-8562"]},"institutions":[{"id":"https://openalex.org/I123044942","display_name":"Universitat Aut\u00f2noma de Barcelona","ror":"https://ror.org/052g8jq94","country_code":"ES","type":"education","lineage":["https://openalex.org/I123044942"]},{"id":"https://openalex.org/I4210086696","display_name":"Biomedical Research Networking Center on Neurodegenerative Diseases","ror":"https://ror.org/00zca7903","country_code":"ES","type":"facility","lineage":["https://openalex.org/I4210086696"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Esther Udina","raw_affiliation_strings":["Institute of Neurosciences and CIBERNED, Universitat Autonoma de Barcelona, Bellaterra, Spain,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Institute of Neurosciences and CIBERNED, Universitat Autonoma de Barcelona, Bellaterra, Spain,","institution_ids":["https://openalex.org/I123044942","https://openalex.org/I4210086696"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012712111","display_name":"Constantine S. Mitsiades","orcid":"https://orcid.org/0000-0003-2321-8005","observed_orcids":["https://orcid.org/0000-0003-2321-8005"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Constantine S. Mitsiades","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA, USA,","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021656597","display_name":"Patrick Yung Wen","orcid":"https://orcid.org/0000-0002-0774-7700","observed_orcids":["https://orcid.org/0000-0002-0774-7700","https://orcid.org/0000-0003-3224-3042","https://orcid.org/0000-0002-2452-0540"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Patrick Y. Wen","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA, USA,","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108715271","display_name":"E. Tessa Hedley\u2010Whyte","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"E. Tessa Hedley-Whyte","raw_affiliation_strings":["Department of Pathology, Massachusetts General Hospital, Boston, MA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pathology, Massachusetts General Hospital, Boston, MA, USA,","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073993417","display_name":"Anne Louise Oaklander","orcid":"https://orcid.org/0000-0002-9578-1596","observed_orcids":["https://orcid.org/0000-0002-9578-1596"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anne Louise Oaklander","raw_affiliation_strings":["Department of Neurology, Massachusetts General Hospital, Boston, MA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Neurology, Massachusetts General Hospital, Boston, MA, USA,","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034777701","display_name":"Johan G. Monbaliu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1330063522","display_name":"Johnson & Johnson (United States)","ror":"https://ror.org/03qd7mz70","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Johan Monbaliu","raw_affiliation_strings":["Johnson & Johnson, GPCD, Beerse, Belgium,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Johnson & Johnson, GPCD, Beerse, Belgium,","institution_ids":["https://openalex.org/I1330063522"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024984035","display_name":"An Vynckier","orcid":"https://orcid.org/0000-0002-7402-1061","observed_orcids":["https://orcid.org/0000-0002-7402-1061"]},"institutions":[{"id":"https://openalex.org/I1330063522","display_name":"Johnson & Johnson (United States)","ror":"https://ror.org/03qd7mz70","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"An Vynckier","raw_affiliation_strings":["Johnson & Johnson, GPCD, Beerse, Belgium,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Johnson & Johnson, GPCD, Beerse, Belgium,","institution_ids":["https://openalex.org/I1330063522"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061423789","display_name":"Lee R. Silverman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405270001","display_name":"Takeda Oncology (United States)","ror":"https://ror.org/05vm7p871","country_code":"US","type":"company","lineage":["https://openalex.org/I4405270001"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lee Silverman","raw_affiliation_strings":["Millennium Pharmaceuticals, Inc., Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Millennium Pharmaceuticals, Inc., Cambridge, MA, USA","institution_ids":["https://openalex.org/I4405270001"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032464400","display_name":"Kenneth Carl Anderson","orcid":"https://orcid.org/0000-0002-6418-0886","observed_orcids":["https://orcid.org/0000-0002-6418-0886"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kenneth C. Anderson","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA, USA,","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5080751235","display_name":"Xavier Navarro","orcid":"https://orcid.org/0000-0001-9849-902X","observed_orcids":["https://orcid.org/0000-0001-9849-902X"]},"institutions":[{"id":"https://openalex.org/I123044942","display_name":"Universitat Aut\u00f2noma de Barcelona","ror":"https://ror.org/052g8jq94","country_code":"ES","type":"education","lineage":["https://openalex.org/I123044942"]},{"id":"https://openalex.org/I4210086696","display_name":"Biomedical Research Networking Center on Neurodegenerative Diseases","ror":"https://ror.org/00zca7903","country_code":"ES","type":"facility","lineage":["https://openalex.org/I4210086696"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Xavier Navarro","raw_affiliation_strings":["Institute of Neurosciences and CIBERNED, Universitat Autonoma de Barcelona, Bellaterra, Spain,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Institute of Neurosciences and CIBERNED, Universitat Autonoma de Barcelona, Bellaterra, Spain,","institution_ids":["https://openalex.org/I123044942","https://openalex.org/I4210086696"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":8,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.6302,"has_fulltext":false,"cited_by_count":5,"citation_normalized_percentile":{"value":0.72064692,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":94},"biblio":{"volume":"114","issue":"22","first_page":"3860","last_page":"3860"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.002099999925121665,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11735","display_name":"Peripheral Neuropathies and Disorders","score":0.0008999999845400453,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/bortezomib","display_name":"bortezomib","score":0.9860000014305115},{"id":"https://openalex.org/keywords/peripheral-neuropathy","display_name":"peripheral neuropathy","score":0.9150000214576721},{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":0.9929999709129333},{"id":"https://openalex.org/keywords/sensory-neuropathy","display_name":"sensory neuropathy","score":0.8650000095367432},{"id":"https://openalex.org/keywords/small-fiber-neuropathy","display_name":"small fiber neuropathy","score":0.8289999961853027},{"id":"https://openalex.org/keywords/nerve-conduction-studies","display_name":"nerve conduction studies","score":0.8040000200271606},{"id":"https://openalex.org/keywords/mouse-model","display_name":"mouse model","score":0.5059999823570251},{"id":"https://openalex.org/keywords/demyelination","display_name":"demyelination","score":0.8920000195503235},{"id":"https://openalex.org/keywords/axonal-injury","display_name":"axonal injury","score":0.8090000152587891},{"id":"https://openalex.org/keywords/myelinated-fiber-loss","display_name":"myelinated fiber loss","score":0.6489999890327454},{"id":"https://openalex.org/keywords/neuroprotective-strategies","display_name":"neuroprotective strategies","score":0.6679999828338623},{"id":"https://openalex.org/keywords/drug-induced-neuropathy","display_name":"drug-induced neuropathy","score":0.5070000290870667},{"id":"https://openalex.org/keywords/neurophysiology","display_name":"neurophysiology","score":0.3440000116825104},{"id":"https://openalex.org/keywords/myelin-thickness","display_name":"myelin thickness","score":0.5630000233650208}],"concepts":[{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.8971062898635864},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7974658012390137},{"id":"https://openalex.org/C2779901536","wikidata":"https://www.wikidata.org/wiki/Q945238","display_name":"Peripheral neuropathy","level":3,"score":0.6202638149261475},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.520072877407074},{"id":"https://openalex.org/C2778843932","wikidata":"https://www.wikidata.org/wiki/Q2018262","display_name":"Axon reflex","level":3,"score":0.4635545313358307},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.45267558097839355},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3746521770954132},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.3392140865325928},{"id":"https://openalex.org/C83974742","wikidata":"https://www.wikidata.org/wiki/Q179405","display_name":"Reflex","level":2,"score":0.1339171826839447},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.09912672638893127},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v114.22.3860.3860","doi":"https://doi.org/10.1182/blood.v114.22.3860.3860","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v114.22.3860.3860","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1849431063","https://openalex.org/W2084842992","https://openalex.org/W7222880080","https://openalex.org/W7096753249","https://openalex.org/W2344318282","https://openalex.org/W2013617101","https://openalex.org/W6906660969","https://openalex.org/W4415496439","https://openalex.org/W6887936601","https://openalex.org/W2549674243"],"abstract_inverted_index":{"Abstract":[0,1],"3860":[2],"Poster":[3],"Board":[4,658,671,686,700,716,731,791,811],"III-796":[5],"Bortezomib":[6],"(Velcade\u00ae)":[7],"therapy":[8],"for":[9,258,500],"multiple":[10],"myeloma":[11],"(MM)":[12],"results":[13],"in":[14,47,86,106,117,138,157,244,252,261,267,272,277,291,309,321,331,357,425,438,451,515,531,553,566,576,593,606,614,628,635],"high":[15],"overall":[16],"and":[17,71,114,129,132,164,185,191,224,235,251,282,312,360,376,393,396,403,444,456,506,519,537,558,569,583,610,619,638,680,745,755,771,777,820],"complete":[18,353],"response":[19],"rates,":[20],"but":[21],"can":[22],"also":[23,177],"lead":[24],"to":[25,34,45,63,72,288,366,460,495,595],"peripheral":[26],"neuropathy":[27,41],"(PN).":[28],"Bortezomib-associated":[29],"PN":[30,69,89,116,137,175,204,237,250,297,306,319,330,375,388,410,493],"has":[31],"been":[32],"shown":[33],"be":[35,367,458],"a":[36,118,139,332,349,385,412,469,497],"cumulative,":[37],"dose-related,":[38],"primarily":[39],"sensory":[40,162,186,318,358,387,538,571,647],"that":[42,80,389,408],"is":[43,61,301,397,411],"reversible":[44,308,462],"baseline":[46,221,605,627],"the":[48,65,82,100,158,245,262,268,324,345,379,461,482,487,507],"majority":[49],"of":[50,135,172,220,323,334,373,415,422,440,447,464,467,491,503,509,544,578,659,672,687,701,717,732,792,812],"cases":[51],"(Richardson":[52,122],"et":[53,123,144,210,431,475],"al,":[54,124,145,211,432,476],"Br":[55],"J":[56,125,146],"Haematol":[57],"2009).":[58,150],"Further":[59],"research":[60],"needed":[62],"determine":[64,73],"mechanisms":[66],"by":[67,205,341,547],"which":[68],"arises":[70],"potential":[74,618,650],"neuroprotective":[75,510],"strategies.":[76,511],"A":[77],"preclinical":[78,130,313,520],"model":[79,142,264,490,526],"reflects":[81],"neurophysiologic":[83,104,131,181,241,342],"changes":[84,242],"seen":[85,243,356],"patients":[87,109,156,247,327],"developing":[88],"during":[90],"bortezomib":[91,113,256,402],"treatment":[92],"would":[93],"prove":[94],"highly":[95],"valuable.":[96],"Here":[97],"we":[98],"assess":[99],"relationship":[101],"between":[102,240,370],"clinical":[103,159,311,371,485,516],"findings":[105,437,514],"untreated":[107],"MM":[108],"who":[110,217,227,328],"received":[111],"single-agent":[112],"developed":[115,161,203,228],"phase":[119],"2":[120],"study":[121,160],"Clin":[126],"Oncol":[127],"2009)":[128],"histologic":[133,361,436],"characterization":[134],"bortezomib-induced":[136,492],"SwissOF1":[140,488],"mouse":[141,263,346,380,489],"(Bruna":[143],"Peripher":[147],"Nerv":[148],"Syst":[149],"By":[151,315],"CTCAE":[152,316],"grading,":[153,317],"41/64":[154],"(64%)":[155],"PN,":[163],"7":[165,215],"(11%)":[166],"had":[167,218,329],"motor":[168,184,608,616,620],"PN.":[169],"In":[170,344],"35":[171,322],"these":[173,199],"patients,":[174,200],"was":[176,307,338,355],"assessed":[178,340],"using":[179],"extensive":[180],"testing,":[182],"including":[183,214],"nerve":[187,643,648],"conduction":[188,644],"studies":[189,271,400],"(NCS)":[190],"quantitative":[192],"sudomotor":[193,636],"axon":[194],"reflex":[195],"testing":[196,549],"(QSART).":[197],"Of":[198],"22/35":[201],"(63%)":[202],"modified":[206],"consensus":[207],"criteria":[208],"(England":[209],"Neurology":[212],"2005),":[213],"(20%)":[216],"worsening":[219],"MM-associated":[222],"neuropathy,":[223],"15":[225,246],"(43%)":[226],"new":[229],"small-fiber":[230,236],"(n=7)":[231],"or":[232,661,674,689,703,719,734,794,814],"both":[233,310,383,391],"large-":[234],"(n=8).":[238],"Similarities":[239],"with":[248,298,382,401,419,453,484],"new-onset":[249],"20":[253],"animals":[254],"given":[255],"twice-weekly":[257],"6":[259],"weeks":[260],"are":[265,450],"summarized":[266],"Table.":[269],"Histologic":[270],"mice":[273,439],"showed":[274],"significant":[275,591,633],"reductions":[276,575],"myelinated":[278,448],"fiber":[279],"count":[280],"(\u20139.9%)":[281],"myelin":[283,473],"thickness":[284],"(\u201317.5%),":[285],"likely":[286],"secondary":[287,445],"axonal":[289,442],"damage,":[290],"bortezomib-treated":[292],"vs":[293],"control":[294],"animals;":[295],"however,":[296],"demyelinating":[299],"features":[300],"uncommon":[302],"clinically.":[303],"Importantly,":[304],"bortezomib-associated":[305,374],"studies.":[314,523],"resolved":[320],"41":[325],"(85%)":[326],"median":[333,607,629],"98":[335],"days":[336],"(reversibility":[337],"not":[339],"testing).":[343],"model,":[347,381],"after":[348],"4-week":[350],"wash-out":[351],"period,":[352],"normalization":[354],"NCS":[359,454],"findings.":[362],"Overall,":[363],"there":[364],"appears":[365,494],"good":[368],"correspondence":[369],"manifestations":[372],"evidence":[377],"from":[378,597,604,626],"showing":[384],"predominantly":[386],"affects":[390],"large":[392],"small":[394],"fibers":[395,449],"reversible.":[398],"Preclinical":[399],"other":[404],"agents":[405],"have":[406],"suggested":[407],"this":[409,504],"mechanism-based":[413],"effect":[414],"proteasome":[416],"inhibitors":[417],"associated":[418],"cytoplasmic":[420],"accumulations":[421],"ubiquitinated":[423],"proteins":[424],"dorsal":[426],"root":[427],"ganglia":[428],"neurons":[429],"(Silverman":[430],"ASH":[433],"2008).":[434,480],"Furthermore,":[435],"mild":[441],"loss":[443,446],"accord":[452],"findings,":[455,486],"may":[457],"due":[459],"disruption":[463],"proteasomal":[465],"degradation":[466],"PMP22,":[468],"glycoprotein":[470],"incorporated":[471],"into":[472],"(Gilardini":[474],"Curr":[477],"Med":[478],"Chem":[479],"Given":[481],"similarities":[483],"represent":[496],"promising":[498],"vehicle":[499],"further":[501],"exploration":[502],"toxicity":[505],"development":[508],"Table":[512],"Neurophysiologic":[513],"(vs":[517,521],"baseline)":[518],"controls)":[522],"Clinical":[524],"Mouse":[525],"Sensory":[527],"function":[528,546,601,623,637],"Significant":[529,542,551,564,574],"increase":[530,592],"Total":[532],"Neuropathy":[533],"Score":[534],"(median":[535,540,555,560,580,586],"9.5)":[536],"score":[539,631],"5)":[541],"impairment":[543],"sensory-motor":[545],"Rotarod":[548],"Large-fiber":[550],"reduction":[552,565],"sural":[554],"\u20133.6":[556],"\u03bcV)":[557,562],"ulnar":[559],"\u20131.8":[561],"SNAP":[563,568],"compound":[567,615],"distal":[570,584],"NCV":[572,621],"Small-fiber":[573],"QSART":[577],"foot":[579],"\u20130.36":[581,587],"\u03bcL)":[582,588],"leg":[585],"Algesimetry":[589],"\u2013":[590],"time":[594],"withdrawal":[596],"hot":[598],"pain":[599],"Motor":[600],"No":[602,612,624,632],"change":[603,625],"signs":[609],"symptoms":[611],"difference":[613,634],"action":[617,649],"Autonomic":[622],"autonomic":[630],"heart":[639],"rate":[640],"variability":[641],"NCV,":[642],"velocity;":[645],"SNAP,":[646],"Disclosures:":[651],"Richardson:":[652],"Keryx:":[653],"Membership":[654,667,682,696,712,727,787,807],"on":[655,668,683,697,713,728,788,808],"an":[656,669,684,698,714,729,789,809],"entity's":[657,670,685,699,715,730,790,810],"Directors":[660,673,688,702,718,733,793,813],"advisory":[662,675,690,704,720,735,795,815],"committees,":[663,676,691,705,721,736,796,816],"Speakers":[664,677,692,706,724,737],"Bureau;":[665,678,693,707,725],"Novartis:":[666,799],"Johnson":[679,744,754],"Johnson:":[681,746,756,772,778,821],"Celgene:":[694],"Consultancy,":[695,711,760,764,785,800,805],"Millennium":[708,824],"Pharmaceuticals,":[709,740,750,767,825],"Inc.:":[710,741,751,768,826],"Research":[722,742,747,752,757,797,802,817,822,827],"Funding,":[723],"BMS:":[726],"Bureau.":[738],"Bruna:Millennium":[739],"Funding;":[743,753,798,803,823],"Funding.":[748,758,818,828],"Udina:Millennium":[749],"Mitsiades:Milllennium:":[759],"Honoraria;":[761],"Novartis":[762],"Pharmaceuticals:":[763],"Honoraria.":[765],"Hedley-Whyte:Millennium":[766],"Consultancy.":[769],"Monbaliu:Johnson":[770],"Employment,":[773,779],"Equity":[774,780],"Ownership.":[775,781],"Vynckier:Johnson":[776],"Silverman:Milllennium:":[782],"Employment.":[783],"Anderson:Celgene:":[784],"Honoraria,":[786,801,806],"Millennium:":[804],"Navarro:Johnson":[819]},"counts_by_year":[{"year":2021,"cited_by_count":1},{"year":2012,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2017-03-03T00:00:00"}